Download Files:
HEC96719
$690 – $5,700
Products Details
Product Description
– HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis[1].
Web ID
– HY-153114
Shipping
– Room temperature
Molecular Formula
– C29H22Cl2N2O5
References
– [1]Cao S, et al. Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis. Eur J Med Chem. 2022 Feb 15;230:114089.
CAS Number
– 2181834-03-5
Molecular Weight
– 549.40
SMILES
– O=C(C1=CC=C2C(OC3=CC=C(OCC4=C(C5CC5)ON=C4C6=C(Cl)C=CC=C6Cl)N=C3C7(CC7)C2)=C1)O
Clinical Information
– Phase 2
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– FXR
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
